Autoimmunity in the Pathogenesis of AF

The Role of Autoimmune Mechanisms in the Pathogenesis of Atrial Fibrillation

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT03498729

Enrollment

Registered

2018-04-17

Start date

2018-03-05

Completion date

2021-12-09

Last updated

2022-02-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Atrial Fibrillation

Keywords

Autoimmune Diseases

Brief summary

This research study is being done to find out whether autoimmune mechanisms are associated with the development of atrial fibrillation.

Detailed description

The study sets out to identify an explanation for the pathogenesis of AF, potentially forming the basis for designing novel targeted therapies to prevent or reverse this prevalent human disease. The overall objectives are to determine whether autoimmune diseases are associated with AF development and to identify specific diagnostic and prognostic biomarkers that will improve the ability to accurately predict risk of AF development. The study will prospectively enroll patients with and without AF and determine their serum cytokine levels and assess the functional responses of T cells on the basis of cytokine production after in vitro T-cell specific stimulation, using Luminex bead-based multiplex technology.

Interventions

OTHERPeripheral Blood Sample

30mL peripheral whole blood sample

Study design

Observational model

CASE_CONTROL

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to 99 Years

Healthy volunteers

Yes

Inclusion criteria

* Cases: AF (Persistent, paroxysmal AF) * Controls 1: (No prior history of AF or inflammatory or autoimmune diseases) * Controls 2: (biopsy proven Psoriasis)

Exclusion criteria

* Clinically apparent acute infections over the past 4 weeks * Chronic infections * Recent malignancies * Recent Radiation or chemotherapy * Chronic kidney disease (≥ stage 2) * Organ transplantation * History of chronic liver disease * Major surgery or invasive procedure in the past 6 months * Internal prosthesis * Receiving immunosuppressive therapy * Known rheumatologic diseases (except for the participants with psoriasis) * Females who are known to be pregnant

Design outcomes

Primary

Measure	Time frame	Description
Cytokines Levels	through study completion, approximately 3 years.	Cytokine Profiles

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026